|
Title
|
Published
|
Price
|
By
GlobalData
rEVO Biologics (rEVO), formerly known as GTC Biotherapeutics, Inc., is a rare disease company. It develops and delivers cost effective first and next-generation human therapeutic proteins. It utilizes its proprietary rPRO technology platform to produ
|
April
2013
|
$
125
|
By
GlobalData
This comprehensive SWOT profile of China Biologic Products, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the
|
March
2013
|
$
300
|
By
GlobalData
Advanced Biologics Corporation (ABC) is a medical device company which carries out the development of innovative and clinically relevant biologic solutions across wide degree of medical devices. The OsteoAMP family of /conductive products are the fir
|
December
2012
|
$
750
|
By
GlobalData
RTI Biologics, Inc. (RTI), formerly Regeneration Technologies, Inc., is a medical device company. It provides tissue-based solutions to repair and promote the natural healing of human bone and other human tissues. The company produces Allograft tissu
|
November
2012
|
$
750
|
By
GlobalData
RTI Biologics, Inc. Market Share Analysis
Summary
GlobalData’s new report, “RTI Biologics, Inc. Market Share Analysis” provides in-depth information on RTI Biologics, Inc.’s market position in the orthobiologics market. The report also provides
|
October
2012
|
$
1000
|
By
GlobalData
Bone Biologics, Inc. (Bone Biologics) is a biotechnology company. The company manufactures orthobiologic products. It develops bone and cartilage regeneration technologies. Its products include University of California Bone-1 (UCB-1) technology, a sk
|
September
2012
|
$
125
|
By
GlobalData
Alpha Biologics Sdn Bhd (Alpha Biologics) is a pharmaceutical and healthcare company, based in Malaysia. It provides contract bio-manufacturing services. The company supplies mammalian cell proteins such as monoclonal antibodies, recombinant proteins
|
August
2012
|
$
250
|
By
GlobalData
ReGen Biologics, Inc. (ReGen) is a public medial equipment company. It primarily focuses on developing, manufacturing and marketing tissue growth and repair products for the US and other parts of the world. The company concentrates on providing minim
|
August
2012
|
$
250
|
By
GlobalData
RTI Biologics, Inc. (RTI), formerly Regeneration Technologies, Inc., is a medical device company. It provides tissue-based solutions to repair and promote the natural healing of human bone and other human tissues. The company produces Allograft tissu
|
August
2012
|
$
250
|
By
GlobalData
China Biologic Products, Inc. (China Biologic) is a biopharmaceutical company. It is engaged in the research, development, production and manufacturing of plasma-based pharmaceutical product products for the prevention and treatment of various diseas
|
August
2012
|
$
250
|
By
Global Markets Direct
Avaxia Biologics, Inc. – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “Avaxia Biologics, Inc. - Product Pipeline Review - 2012” provides data on the Avaxia Biologics, Inc.’s research and development focu
|
July
2012
|
$
500
|
By
GlobalData
Synthetic Biologics, Inc. (Synthetic Biologics), formally known as Adeona Pharmaceuticals, Inc., a public share holding company, is a development-stage specialty pharmaceutical company. The company is principally focused to in-license drug candidates
|
March
2012
|
$
250
|
By
Global Markets Direct
Global Market Direct’s pharmaceuticals report, “Heat Biologics, Inc. - Product Pipeline Review - H2 2011” provides data on the Heat Biologics, Inc.’s research and development focus. The report includes information on current developmental pipeline, c
|
October
2011
|
$
500
|
By
Global Markets Direct
Global Market Direct’s pharmaceuticals report, “Actis Biologics, Inc - Product Pipeline Review - H2 2011” provides data on the Actis Biologics, Inc’s research and development focus. The report includes information on current developmental pipeline, c
|
October
2011
|
$
500
|
By
IMARC Group
With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate. This market, however, unlike small molecule generics, is expected to be more akin to a maratho
|
October
2011
|
$
1200
|
By
Global Markets Direct
Global Market Direct’s pharmaceuticals report, “Actis Biologics, Inc - Product Pipeline Review - Q1 2011” provides data on the company’s research and development f...
|
May
2011
|
$
500
|
By
Global Markets Direct
Global Market Direct’s pharmaceuticals report, “Heat Biologics, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development f...
|
May
2011
|
$
500
|
By
GlobalData
This report is a source for data, analysis and actionable intelligence on the Aperion Biologics Corporation portfolio of pipeline products. The report provides detailed analysis on each pipeline product with i...
|
March
2011
|
$
750
|
By
Life Science Analytics
Report contains the company’s contact information, business , company details, tables, graphs and listings of the number of deals by deal category (product, technology, miscellaneous), stag...
|
March
2011
|
$
600
|
By
Life Science Analytics
Report contains the company’s contact information, business , company details, tables, graphs and listings of the number of deals by deal category (produ...
|
March
2011
|
$
600
|
By
Life Science Analytics
Report contains the company’s contact information, business , company details, tables, graphs and listings of the number of deals by deal category (pr...
|
March
2011
|
$
600
|
By
Life Science Analytics
provides up to date insight into company’s business description, product information, pipeline details including both information and detailed individual product records.S...
|
March
2011
|
$
750
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage o...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of d...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication an...
|
March
2011
|
$
350
|
By
Life Science Analytics
Report includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of ...
|
March
2011
|
$
350
|
By
GlobalData
Green Biologics Limited (GBL) is an industrial biotech company. The company is engaged in the development of advanced fermentation technologies f...
|
March
2011
|
$
250
|
By
ICON Group International, Inc.
This econometric study covers the world outlook for biologics across more than 200 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millio...
|
January
2011
|
$
795
|
By
ICON Group International, Inc.
This econometric study covers the latent demand outlook for biologics across the regions of Greater China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing,...
|
January
2011
|
$
495
|
By
Koncept Analytics
Biosimilars or FOBs (Follow-on biologics) refer to generic versions of patented branded biological drugs, developed subsequent to the patent expiry of brand name products. The biosimilars market is segmented into peptides, recombinant glyco...
|
November
2010
|
$
800
|
By
Life Science Analytics
report contains detailed information on pipelines by phase and therapeutic indication as well as management information,deals and alliances and recent news...
|
July
2010
|
$
750
|
By
Life Science Analytics
report contains detailed information on pipelines by phase and therapeutic indication as well as management information,deals and alliances and recent news on...
|
July
2010
|
$
750
|
By
Life Science Analytics
report contains detailed information on pipelines by phase and therapeutic indication as well as management informat...
|
July
2010
|
$
750
|
By
Life Science Analytics
report contains detailed information on pipelines by phase and therapeutic indication as well as management information,deals and alliances and recent news o...
|
July
2010
|
$
750
|
By
Life Science Analytics
report contains detailed information on pipelines by phase and therapeutic indication as well as management information,deals and alliances and recent news on the company including ke...
|
July
2010
|
$
750
|
By
Life Science Analytics
Mentor Corporation-Deals & Alliances Report contains the company’s contact information, business , company details, tables, graphs and listings of the number of deals by deal category (product, technology, miscellaneous), stage of de...
|
July
2010
|
$
600
|
By
Life Science Analytics
Bayer Ag-Deals & Alliances Report contains the company’s contact information, business , company details, tables, graphs and listings of the number of deals by deal category (product, technology, miscellaneous), stage of development,...
|
July
2010
|
$
600
|
By
Life Science Analytics
Evotec AG-Deals & Alliances Report contains the company’s contact information, business , company details, tables, graphs and listings of the number of deals by deal category (product, technology, miscellaneous), stage of development...
|
July
2010
|
$
600
|
By
Life Science Analytics
includes a business , tabular representation of the number and percentage of products in each therapeutic indication, all company products lis...
|
January
2010
|
$
350
|